Form 4: Vir Bio EVP Sells Shares for Tax Obligations

Vir Biotechnology's EVP and General Counsel, Vanina de Verneuil, sold 1,365 shares of common stock to cover tax withholding obligations.

Summary

• Vanina de Verneuil, Executive Vice President and General Counsel of Vir Biotechnology, Inc., reported a transaction involving the company's common stock.
• On November 3, 2025, 1,365 shares of common stock were sold at a price of $5.863 per share.
• This sale was an automatic transaction executed to cover tax withholding and remittance obligations associated with the vesting of restricted stock units.
• The transaction was conducted pursuant to a Rule 10b5-1(c) plan, indicating it was pre-scheduled.
• Following this transaction, Vanina de Verneuil beneficially owns 80,595 shares of Vir Biotechnology common stock.
• The reported beneficial ownership includes 2,500 shares acquired on May 30, 2025, through an employee stock purchase program.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine, non-discretionary sale for tax purposes, which is a common occurrence for executives with equity compensation and generally not indicative of company performance or future prospects.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, which typically signifies a pre-scheduled and automated sale, reducing concerns about discretionary timing based on insider information.
• The sale's stated purpose was to cover tax withholding obligations, a routine event for executives receiving equity compensation, rather than a discretionary sale of shares.

Negatives

• A reduction in direct beneficial ownership by an executive, even if for tax purposes, represents a slight decrease in their direct equity alignment with shareholders.

Future Outlook

N/A

Industry Context

This is a routine insider transaction for tax purposes, common across all industries for executives receiving equity compensation. It does not reflect specific industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact, as this is a small, non-discretionary sale for tax purposes and does not signal a change in management's confidence or company fundamentals.
• Employees: No direct impact on the broader employee base.

Key Dates

Keywords

Vir Biotechnology, VIR, Form 4, Insider Transaction, Stock Sale, Executive Compensation, Tax Withholding, Restricted Stock Units, Rule 10b5-1, Vanina de Verneuil